Supporting Federal Decision Making through Participatory Technology Assessment
Summary
The incoming administration faces complex issues at the intersections of science, technology, and society. As such, the next administration should establish a special unit within the Science and Technology Policy Institute (STPI)—an existing federally funded research and development center (FFRDC)—to provide capacity for Participatory Technology Assessment (pTA) to the White House Office of Science and Technology Policy and across executive branch agencies.
A pTA unit within STPI would provide pTA as a service for the executive branch regarding emerging scientific and technological issues and questions. By integrating public voices alongside expert assessments, the next administration can ensure that federal science and technology decisions provide the greatest benefit to society.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.
By leveraging its substantial purchasing power responsibly, the government can encourage high-quality, inclusive AI solutions that address diverse citizen needs while setting a strong precedent for innovation and accountability.
The federal government should expand the FDA’s priority review voucher program and provide market exclusivity advantages to encourage the development of medications for addiction.